3D MOLECULAR DOCKING COMBINED WITH AI-DRIVEN VIRTUAL SCREENING TO REPURPOSE FDA-APPROVED DRUGS FOR RARE NEURODEGENERATIVE DISEASES. Int. J. Exp. Biol. 2024, 2 (01), 50-73.